Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PRV-002 in Healthy Volunteers
NCT05033444Phase 1Completed
- Sponsor
- Odyssey Therapeutics
- Start
- Feb 2022
- Primary completion
- Oct 2022
- Modality
- Nanoparticles, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in traumatic brain injury (TBI) comparing PRV-002 with Placebo (2 arms). Primary endpoints: Incidence, severity, and relationship of AEs/SAEs, Change from baseline in vital signs and 4 more. Started Feb 2022; status: completed.
02
Drugs
ONP-002
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05033444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05033444.